Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
The U.S. FDA granted Roche Holding AG breakthrough device designation for its Elecsys Neurofilament Light Chain test for multiple sclerosis. The Elecsys NfL test can aid in the detection of disease ...
A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...
An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...
MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...
Presentation raises questions about EBV timing. Dalia Rotstein, MD, of the University of Toronto, discussed the findings and their implications in an oral presentation at the Amer ...
Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...
Investigators have identified patients who tested positive for the Epstein-Barr Virus 9 years after they were diagnosed with MS, challenging the prevailing notion that the virus precedes MS.
A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...
TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...